US Contrast Media Injectors Market Analysis, Size, and Share by 2027

The US contrast media injectors market is expected to reach US$ 350.4 Mn in 2027 from US$ 183.8 Mn in 2018. The market is estimated to grow with a CAGR of 7.5% from 2019-2027.

The growth of the market is driven by the factors such as increasing number of approvals for contrast agents and increasing number of patients suffering with chronic diseases. However, the market is likely to get affected due to side effects associated with the contrast media agents during the forecast period.

In an aging society where chronic diseases is a leading factor in the health system, technical advancements are necessary to preserve the quality of life through keeping the affordable prices. Chronic diseases can be defined as medical conditions that lasts for one year or more and requires ongoing medical attention or limit activities of daily living. Chronic diseases such as cancer, heart diseases, musculoskeletal diseases, and others are the leading causes of death and disability that requires several imaging modalities for diagnostic and treatment monitoring purposes. According to the National Center for Chronic Disease Prevention and Health Promotion, chronic diseases takes up US$3.3 trillion in annual health care costs.

Additionally, there presence of robust products in the pipeline have been witnessed in the contrast media injectors market. For instance, Lantheus Medical Imaging, Inc., a US based medical imaging company actively involved in the commercialization of contrast media injectors and agents is undergoing clinical trials to develop Flurpiridaz F 18, a novel PET agent, with the first of two Phase 3 trials complete. Moreover, the company has also collaborated with academic centers in the U.S., Canada and the Europe to investigate fluorine-18-based positron emission tomography (PET) radiopharmaceutical imaging agent designed for molecular imaging of the norepinephrine pathway.

The US contrast media injectors market is segmented based on product and application. Among the product segment, the consumables segment is expected to grow at a significant rate of 7.7% during the forecast period. In addition, the segment is also anticipated to dominate the market by products during the year 2027, with a market share of around 65.0%

 US Contrast Media Injectors Market Revenue and Forecasts to 2027 (US$ Mn)

US CONTRAST MEDIA INJECTORS– MARKET SEGMENTATION

By Product

• Injector Systems
  • MRI Injector Systems
  • CT Injector Systems
  • Angiography Injector Systems
• Consumables
  • Injector Heads
    • Single Head Injectors
    • Dual Head Injectors
    • Syringe less Injectors
  • Tubing
  • Syringes
  • Other Consumables
• Accessories

US CONTRAST MEDIA INJECTORS – MARKET SEGMENTATION

By Application

• Interventional Cardiology
• Interventional Radiology
• Radiology

Companies Mentioned

• Boston Scientific Corporation
• Shenzhen Xinguan Electromechanical Co. Ltd.
• ulrich GmbH & Co.KG
• APOLLO RT Co. Ltd.
• Bracco Imaging S.p.A.
• Guerbet SA
• Cook Medical Incorporated
• Smiths Medical
• Sino Medical-Device Technology Co., Ltd.
• Bayer AG
• Nemoto Kyorindo Co., Ltd
• General Electric
• AngioDynamics

US Contrast Media Injectors Report Scope